Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 1
2021 2
2022 8
2023 5
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial.
Shiina K, Tomiyama H, Tanaka A, Imai T, Hisauchi I, Taguchi I, Sezai A, Toyoda S, Dohi K, Kamiya H, Kida K, Anzai T, Chikamori T, Node K; CANDLE trial investigators. Shiina K, et al. Hypertens Res. 2023 Feb;46(2):495-506. doi: 10.1038/s41440-022-01085-x. Epub 2022 Nov 15. Hypertens Res. 2023. PMID: 36380202
Effects of canagliflozin on NT-proBNP stratified by left ventricular diastolic function in patients with type 2 diabetes and chronic heart failure: a sub analysis of the CANDLE trial.
Kusunose K, Imai T, Tanaka A, Dohi K, Shiina K, Yamada T, Kida K, Eguchi K, Teragawa H, Takeishi Y, Ohte N, Yamada H, Sata M, Node K; CANDLE Trial Investigators. Kusunose K, et al. Cardiovasc Diabetol. 2021 Sep 14;20(1):186. doi: 10.1186/s12933-021-01380-w. Cardiovasc Diabetol. 2021. PMID: 34521417 Free PMC article. Clinical Trial.
Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial.
Tanaka A, Imai T, Shimabukuro M, Taguchi I, Sezai A, Toyoda S, Watada H, Ako J, Node K; CANDLE trial investigators. Tanaka A, et al. Cardiovasc Diabetol. 2022 Aug 8;21(1):151. doi: 10.1186/s12933-022-01589-3. Cardiovasc Diabetol. 2022. PMID: 35941584 Free PMC article. Clinical Trial.
Mediators of the effects of canagliflozin on N-terminal pro-brain natriuretic peptide concentration: An exploratory mediation analysis of the randomized CANDLE trial.
Tanaka A, Imai T, Suzuki M, Hiramitsu S, Takahashi N, Kadokami T, Kiyosue A, Nishino M, Sakata Y, Node K; CANDLE trial investigators. Tanaka A, et al. Diabetes Obes Metab. 2022 May;24(5):962-965. doi: 10.1111/dom.14656. Epub 2022 Feb 21. Diabetes Obes Metab. 2022. PMID: 35112456 Clinical Trial. No abstract available.
Influence of left ventricular ejection fraction on the reduction in N-terminal pro-brain natriuretic peptide by canagliflozin in patients with heart failure and type 2 diabetes: A sub analysis of the CANDLE trial.
Ohte N, Tanaka A, Kitada S, Yamada T, Eguchi K, Teragawa H, Takeishi Y, Kodama K, Seo Y, Node K; CANDLE Trial Investigators. Ohte N, et al. J Cardiol. 2023 Jun;81(6):508-512. doi: 10.1016/j.jjcc.2022.11.012. Epub 2022 Dec 5. J Cardiol. 2023. PMID: 36481298 Free article. Clinical Trial.
Body fluid regulation via chronic inhibition of sodium-glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trial.
Fujiki S, Tanaka A, Imai T, Shimabukuro M, Uehara H, Nakamura I, Matsunaga K, Suzuki M, Kashimura T, Minamino T, Inomata T, Node K; CANDLE Trial Investigators. Fujiki S, et al. Clin Res Cardiol. 2023 Jan;112(1):87-97. doi: 10.1007/s00392-022-02049-4. Epub 2022 Jun 22. Clin Res Cardiol. 2023. PMID: 35729430 Clinical Trial.
12 results